Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience
Annals of Transplantation · 2023
DOI: 10.12659/aot.941456 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Transplantation, 2023. Verfasst von Masato Shizuku und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantation Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Liver Transplantation, Kidney Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND The management and fate of liver transplant (LT) recipients with preformed donor-specific antibodies (pDSA) remain controversial. The aim of this study was to evaluate the clinical impact of rituximab desensitization on pDSA in LT recipients. MATERIAL AND METHODS This retrospective observational study enrolled 120 LT patients aged ≥18 years. Patients with pDSA were administered 500 mg/body rituximab 1-21 days before LT, except for those who had an active infection or had insufficient time to receive rituximab. We allocated patients to groups with or without pDSA, and then divided patients with pDSA into rituximab (+) and rituximab (-) groups for further analysis. RESULTS Twenty-three patients (19.2%) with pDSA were identified. Of these, 18 received rituximab and 5 did not receive rituximab. No patients developed adverse events related to rituximab. In both groups, the levels of pDSA class I in all patients were decreased immediately after LT, whereas those of pDSA class II decreased slowly. There were no significant differences in pathology findings and overall survival between patients with pDSA who were rituximab (+) or rituximab (-), and between patients with or without pDSA. CONCLUSIONS Rituximab desensitization for LT patients with pDSA was managed successfully without significant complications. Due to the small sample size, we could not demonstrate the benefit of rituximab desensitization for LT patients compared with the rituximab (-) group. Additionally, clinical outcomes in patients with pDSA, with or without rituximab, were similar to those without pDSA. Rituximab desensitization might be not essential for LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Transplantation Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
- Department of Transplantation Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
- Department of Surgery, Renal Transplant Surgery, Aichi medical University, Nagakute, Aichi, Japan.
ORCID-Profile: Masato Shizuku, Nobuhiko Kurata, Kanta Jobara, Yasuhiro Fujimoto, Yasuhiro Ogura
Zitieren
APA
Shizuku, M., Kurata, N., Jobara, K., Fujimoto, Y., & Ogura, Y. (2023). Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience. Annals of Transplantation. https://doi.org/10.12659/aot.941456
Vancouver
Shizuku M, Kurata N, Jobara K, Fujimoto Y, Ogura Y. Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience. Annals of Transplantation. 2023. doi:10.12659/aot.941456
BibTeX
@article{Shizuku2023,
author = {Shizuku, Masato and Kurata, Nobuhiko and Jobara, Kanta and Fujimoto, Yasuhiro and Ogura, Yasuhiro},
title = {Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience},
journal = {Annals of Transplantation},
year = {2023},
doi = {10.12659/aot.941456}
}
EUVIMED